Compare Aurora Cannabis Inc (ACB) vs American Express Co (AXP) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

AXP trades at $349.58, down 0.68% on the day, with a bullish technical outlook and strong fundamentals. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.13% margin. Recent earnings beat expectations in Q1 2026, and analyst consensus targets $376.36. The stock benefits from premium cardholder growth and strategic partnerships.

Outlook remains positive with mid-teens earnings growth potential, though risks include consumer spending sensitivity and competitive pressures. Institutional sentiment is mixed with 38.6% buy ratings. The current price near $350 offers upside to the consensus target, supported by operational cash flow strength and dividend stability.